• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Biofrontera Inc.

    11/13/24 5:16:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRI alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on __________________

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    BIOFRONTERA INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   47-3765675

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

     

    120 Presidential Way, Suite 330

    Woburn, Massachusetts 01801

    (Address of principal executive offices) (Zip code)

     

    BIOFRONTERA INC. 2021 OMNIBUS INCENTIVE PLAN

    (Full title of the plan)

     

    Prof. Dr. Hermann Luebbert

    Chairman and Chief Executive Officer

    Biofrontera Inc.
    120 Presidential Way, Suite 330
    Woburn, MA 01801
    (Name and address of agent for service)
    (781) 245-1325
    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Robert B. Lamm, Esq.

    Gunster, Yoakley & Stewart, P.A.

    4855 Technology Way, Suite 630

    Boca Raton, FL 33431

    Telephone: 954- 468-1321

     

    Daniel Hakansson

    Corporate Counsel

    Biofrontera Inc.

    120 Presidential Way, Suite 330

    Woburn, MA 01801

    Telephone: 781-486-1510

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”).

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 is being filed by Biofrontera Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 3,612,500 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), available for issuance in connection with equity-based awards granted under the Biofrontera 2021 Omnibus Incentive Plan, as amended (the “Plan”). The Plan was adopted by the Company’s Board of Directors and approved by the Company’s then sole stockholder on July 23, 2021. The Company registered 137,500 shares of Common Stock for issuance under the Plan on a Registration Statement on Form S-8 (File No. 333-265463) (the “Initial Registration Statement”), filed with the Commission on June 7, 2022. On December 12, 2022, the stockholders of the Company approved an amendment to the Plan to increase the number of shares authorized for issuance by 129,490 shares, from 137,500 shares to 266,990 shares. On June 12, 2024, the stockholders of the Company approved a further amendment to the Plan to increase the number of shares authorized for issuance by 3,483,010 shares, from 266,990 shares to 3,750,000 shares. In accordance with Section E of the General Instructions to Form S-8, the contents of the Initial Registration Statement are incorporated by reference herein, except that the information contained in Part II of the Initial Registration Statement has been modified as set forth herein.

     

     
     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    References in this registration statement to “we,” “us,” “our,” and the “Company,” or similar references, refer to Biofrontera Inc., unless otherwise stated or the context otherwise requires.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duties, except where the director or officer breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct, knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law, or obtained an improper personal benefit. Our amended and restated certificate of incorporation relieves the directors, but not the officers, of the Company from personally liability to the Company and its stockholders in accordance with the foregoing description.

     

    Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Our amended and restated certificate of incorporation and amended and restated bylaws provide indemnification for our directors and officers to the fullest extent permitted by the General Corporation Law of the State of Delaware. We will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

     

    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

     

     
     

     

    Item 8. Exhibits.

     

    The following documents are filed as exhibits to this registration statement:

     

    Exhibit Number   Description of Exhibit
    4.1   Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2021).
    4.2   Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on November 3, 2021).
    4.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Biofrontera Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 3, 2023).
    4.4   Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of Biofrontera Inc. filed April 25, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2024).
    4.5   Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to Amendment No. 6 to the Company’s registration statement on Form S-1 filed with the SEC on October 12, 2021).
    4.6   Biofrontera Inc. 2021 Omnibus Incentive Plan (as amended and restated on June 12, 2024) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 14, 2024).
    5.1*   Opinion of Gunster, Yoakley & Stewart, P.A.
    23.1*   Consent of Marcum LLP
    23.2*   Consent of Gunster, Yoakley & Stewart, P.A. (included in Exhibit 5.1).
    24.1*   Powers of Attorney (included on the signature page of this registration statement).
    107*   Filing Fee Table

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

     
     

     

    (2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction, the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Commonwealth of Massachusetts, on November 13, 2024.

     

      BIOFRONTERA INC.
         
      By: /s/ E. Fred Leffler, III
      Name: E. Fred Leffler, III
      Title: Chief Financial Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel Hakansson, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto, and to take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Hermann Luebbert   Chairman and Chief Executive Officer   November 13, 2024
    Hermann Luebbert   (Principal Executive Officer )    
             
    /s/ E. Fred Leffler, III   Chief Financial Officer   November 13, 2024
    E. Fred Leffler, III   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Heikki Lanckriet   Director   November 13, 2024
    Heikki Lanckriet        
             
    /s/ Beth J. Hoffman   Director   November 13, 2024
    Beth J. Hoffman        

     

     

     

    Get the next $BFRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRI

    DatePrice TargetRatingAnalyst
    12/15/2021$11.00Buy
    Benchmark
    11/24/2021$20.00Buy
    Roth Capital
    More analyst ratings

    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Link Christian Alexander Ansgar

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:53:07 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Vv Beteiligungen Aktiengesellschaft claimed ownership of 458,884 shares (SEC Form 3)

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:47:57 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Delphi Unternehmensberatung Aktiengesellschaft claimed ownership of 458,884 shares (SEC Form 3)

    3 - Biofrontera Inc. (0001858685) (Issuer)

    9/30/25 8:42:21 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on Biofrontera with a new price target

    Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00

    12/15/21 6:49:18 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Biofrontera with a new price target

    Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00

    11/24/21 8:02:09 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.

    SCHEDULE 13G/A - Biofrontera Inc. (0001858685) (Subject)

    1/28/26 2:10:17 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    1/13/26 8:35:24 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Biofrontera Inc.

    8-K - Biofrontera Inc. (0001858685) (Filer)

    1/7/26 4:30:50 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

    Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database lock of two clinical studies evaluating Ameluz® PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026. The databases for th

    1/8/26 8:45:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

    • Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz® and the RhodoLED® Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)• In addition, 19 international patent applications and/or registered designs for RhodoLED® lamps outside of the US were acquired and registration of the transfer has been initiated WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofron

    12/18/25 8:45:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and nine months ended September 30, 2025 and provided a business update. Financial highlights Revenues for the first nine months of 2025 were stable with $24.6 million compared to $24.8 million for the same period in 2024The 2025 result was achieved without the buy-in effects from a price increaseIn 3Q25 revenues were $7.0 million, lagging behind the

    11/13/25 8:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

    WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference CallDate:Thursday,

    11/6/25 4:01:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Leadership Updates

    Live Leadership Updates

    View All

    Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

    Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al

    8/11/25 4:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

    WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

    8/29/23 8:00:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

    WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

    7/12/23 8:00:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 3:54:03 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 1:13:39 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/13/24 2:12:35 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care